Vir Biotechnology (VIR) Depreciation & Amortization (CF) (2018 - 2026)

Vir Biotechnology has disclosed Depreciation & Amortization (CF) across 9 years of filings, most recently posting $2.8 million for Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $2.8 million, down 1.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.6 million (down 9.95% YoY), and the FY2025 annual result was $11.7 million, down 19.77% from the prior year.
• Depreciation & Amortization (CF) came in at $2.8 million for Q1 2026 at Vir Biotechnology, down from $2.9 million in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $5.6 million in Q1 2023 to a low of $1.4 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $2.9 million (2025), against an average of $3.2 million.
• Across the five-year window, Depreciation & Amortization (CF) soared 297.32% in 2023 and sank 36.53% in 2025, its largest moves.
• Vir Biotechnology's Depreciation & Amortization (CF) stood at $2.4 million in 2022, then surged by 90.43% to $4.5 million in 2023, then sank by 35.57% to $2.9 million in 2024, then gained by 0.42% to $2.9 million in 2025, then retreated by 3.0% to $2.8 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $2.8 million (Q1 2026), $2.9 million (Q4 2025), and $3.0 million (Q3 2025), per Business Quant data.